Paper Review — verify claims with raw data

What this review does well

• Integrates genomic (chromatin signatures, RNA-Seq) and locus-focused functional literature linking lncRNAs to CNS development and disease Fenoglio et al. 2013 review summary
• Presents concrete disease-linked examples (BACE1-AS in AD; BC200 in aging/AD; Ube3a-as in Angelman; HAR1 in HD; DISC2/Gomafu in psychiatric disease) and mechanisms (antisense regulation, ceRNA/sponging, chromatin recruitment).
• Clear discussion of therapeutic/diagnostic potential and the methodological gaps that must be addressed.

Main limitations & blindspots

1. Predominantly narrative — selection bias and heterogeneous source methods reduce quantitative weighting (no systematic meta-analysis).
2. Many lncRNA–disease links are correlative; fewer locus-specific loss/gain-of-function examples in relevant adult CNS models were available in 2013.
3. Cross-species conservation and cell-type specificity (neurons vs glia; subregions) complicate translation; review notes but cannot resolve these gaps.

Critical synthesis (visual first, then short explanation)

Fenoglio et al. (2013) compiled cross-disciplinary evidence that: (1) lncRNAs are numerous and brain-region/cell-type restricted; (2) many interact with chromatin modifiers (PRC2, G9a) and regulate imprinting/XCI; (3) specific lncRNAs show disease-associated dysregulation across AD, HD, Angelman, epilepsy and psychiatric disorders; and (4) therapeutic targeting of lncRNAs is conceptually attractive but experimentally early-stage and technically challenging Fenoglio et al. 2013 evidence synthesis

Where claims are strongest

• Existence of abundant, brain-specific lncRNAs and their developmental/regional regulation — supported by transcriptomic surveys cited in the review.
• Mechanistic examples where lncRNAs recruit chromatin-modifying complexes (Xist, HOTAIR, Airn) — multiple locus-focused studies provide plausible mechanisms.

Where evidence is weak/moderate

• Disease causation: many disease associations are correlative (postmortem expression changes) without direct proof that lncRNA dysregulation initiates or drives pathology.
• Translational feasibility: delivery, specificity, and off-target effects of RNA-targeted therapies in the human CNS are not solved and were only hypothesised in 2013.

Concrete next steps recommended (by reviewer)

1. Large, well-controlled RNA-Seq and single-nucleus RNA-Seq cohorts across disease stages and regions to quantify reproducible lncRNA dysregulation.
2. Systematic functional perturbation (CRISPRi/a, antisense oligos) in cell-type–specific human iPSC-derived neurons/glia and matched in vivo models with physiological endpoints.
3. Integration with epigenomics (ChIP-Seq, ATAC-Seq) and proteomics to map lncRNA-binding partners and causal chains from lncRNA → chromatin/RNA → phenotype.

Fenoglio et al. 2013 review